FDA Extends Review Period For Eurand’s ZENPEPTM Pancreatic Enzyme Replacement Therapy

Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced that the U.S. Food and Drug Administration (FDA) has advised the Company that it has extended the June 2009 user fee goal date for the New Drug Application for ZENPEP? (pancrelipase capsules) by three months.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on June 25th, 2009